Skip to Content


In the US, Ramucirumab (ramucirumab systemic) is a member of the drug class VEGF/VEGFR inhibitors and is used to treat Colorectal Cancer, Gastric Cancer, Non-Small Cell Lung Cancer and Stomach Cancer.

US matches:



CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Antineoplastic agent

Monoclonal antibody

Angiogenesis inhibitor

Vascular endothelial growth factor receptor 2 (VEGFR2) antagonist

Chemical Name

immunoglobulin G1-kappa, anti-[Homo sapiensvascular endothelial growth factor receptor 2 (VEGFR2,KDR,kinase insert domain receptor, FLK1,CD309) extracellular domain], Homo sapiensmonoclonal antibody; gamma1 haevy chain (1-446) [Homo sapiensVH (IGHV3-21*01 (WHO)

Foreign Names

  • Ramucirumabum (Latin)
  • Ramucirumab (German)
  • Ramucirumab (French)
  • Ramucirumab (Spanish)

Generic Names

  • Ramucirumab (OS: USAN)

Brand Names

  • Cyramza
    Eli Lilly, Switzerland; Eli Lilly, Croatia (Hrvatska); Eli Lilly, Ireland; Eli Lilly, Poland; Eli Lilly and Company, United Kingdom; Eli Lilly and Company, United States; Lilly, Germany; Lilly, France; Lilly, Slovenia; Lilly, Slovakia


ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.